Decreased tumstatin-mRNA is associated with poor outcome in patients with NSCLC

IUBMB Life

Volumn 64, Issue 5, 2012, Pages 423-431

  Luo, Yi Qin ^a   Ming, Zhou ^a   Zhao, Liang ^a   Yao, Li Juan ^a   Dong, Hang ^a   Du, Jian Ping ^a   Wu, Shuang Zheng ^a   Hu, Wen ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Non small cell lung cancer; Prognostic factors; Tumstatin mRNA expression

Indexed keywords

CD34 ANTIGEN; MESSENGER RNA; TUMSTATIN;

ADULT; ANGIOGENESIS; ARTICLE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TUMOR VASCULARIZATION;

AGED; AUTOANTIGENS; CARCINOMA, NON-SMALL-CELL LUNG; COLLAGEN TYPE IV; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICROVESSELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84859804268     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1016     Document Type: Article

References (33)

1. Zhang, S. W, Chen, W. Q., Kong, L. Z. (2007) An annual report: cancer incidence in 35 Cancer Registries in China, 2003. Bullet. Chin. Cancer 16, 494-507.
2. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P. (2005) Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108. (Pubitemid 40372904)
3. Youlden, D. R., Cramb, S. M., Baade, P. D. (2008) The international epidemiology of lung cancer: geographical distribution and secular trends. J. Thoracic Oncol. 3, 819-831.
4. Folkman, J. (1995) Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757-1763.
5. Folkman, J., Sning, Y. (1992) Angiogenesis. J. Biol. Chem. 267, 10931-10934.
6. Macchiarini, P., Gonatanini, G., Hardin, M. J., Squartini, F., Angiletti, G. A. (1992) Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet 340, 145-146.
7. Yuan, A., Yang, P. C., Yu, C. J., Lee, Y. C., Yao, Y. T., et al. (1995) Tumor angiogenesis correlates with histologic type and metastasis in non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 152, 2157-2162. (Pubitemid 3019578)
8. Maeshima, Y., Colorado, P. C., Torre, A., Holthaus, K. A., Grunkemeyer, J. A., et al. (2000) Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275, 21340-21348. (Pubitemid 30481833)
9. Maeshima, Y., Colorado, P. C., Kalluri, R. (2000) Two RGD independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 275, 23745-23750. (Pubitemid 30624661)
10. McCawley, L. J., Matrisian, L. M. (2001) Matrix metalloproteinases: they're not just for matrix anymore. Curr. Opin. Cell Biol. 13, 534-540. (Pubitemid 32817010)
11. Hamano, Y., Zeisberg, M., Sugimoto, H., Lively, J. C., Maeshima, Y., et al. (2003) Physiological levels of tumstatin, a fragment of collagen IV a3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αvβ3 integrin. Cancer Cell 3, 589-601. (Pubitemid 36808653)
12. Maeshima, Y., Sudhakar, A., Lively, J. C., Ueki, K., Kharbanda, S., et al. (2002) Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295, 140-143. (Pubitemid 34052365)
13. Sudhakar, A., Sugimoto, H., Yang, C., Lively, J., Zeisberg, M., et al. (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc. Natl. Acad. Sci. USA 100, 4766-4771. (Pubitemid 36457804)
14. Caudroy, S., Cucherousset, J., Lorenzato, M., Zahm, J. M., Martinella-Catusse, C., et al. (2004) Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas. Hum. Pathol. 35, 1218-1222. (Pubitemid 39361644)
15. Yi-Qin, L., Li-Juan, Y., Liang, Z., An-Yuan, S., Hang, D., et al. (2010) Development of an ELISA for quantification of tumstatin in serum samples and tissue extracts of patients with lung carcinoma. Clin. Chim. Acta 411, 510-515.
16. Moutain, C. F. (1986) A new international staging system for lung cancer. Chest 89, 225s-233s.
17. World Health Organization.(1982) Histological typing of lung tumors. Am. J. Clin. Pathol. 77, 123-136.
18. Yuan, A., Yu, C. J., Kuo, S. H., Chen, W. J., Lin, F. Y., et al. (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol. 19, 432-441. (Pubitemid 32112856)
19. Yuan. A., Yu, C. J., Chen, W. J., Lin, F. Y., Kuo, S. H., et al. (2000) Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int. J. Cancer 89, 475-483.
20. Rigau, V., Molina, T. J., Chaffaud, C., Huchon, G., Audouin, J., et al. (2002) Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence. Lung Cancer 38, 169-176. (Pubitemid 35154382)
21. Maeshima, Y., Colorado, P. C., Kalluri, R. (2000) Two RGD-independent alpha v beta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 75, 23745-23750. (Pubitemid 30624661)
22. Maeshima, Y., Sudhakar, A., Lively, J. C., Ueki, K., Kharbanda, S., et al. (2002) Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295, 140-143. (Pubitemid 34052365)
23. Yuan, A., Yu, C. J., Chen, W. J., Lin, F. Y., Kuo, S. H., et al. (2000) Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int. J. Cancer 89, 475-483.
24. Martinella-Catusse, C., Polette, M., Noel, A., Gilles, C., Dehan, P., et al. (2001) Down-regulation of MT1-MMP expression by the α3 chain of type IV collagen inhibits bronchial tumor cell line invasion. Lab. Invest. 81, 167-175. (Pubitemid 32176380)
25. Burgess, J. K., Boustany, S., Moir, L. M., Weckmann, M., Lau, J. Y., et al. (2010) Reduction of tumstatin in asthmatic airways contributes to angiogenesis, inflammation, and hyperresponsiveness. Am. J. Respir. Crit. Care Med. 181, 106-115.
26. Boosani, C. S., Mannam, A. P., Cosgrove, D., Silva, R., Hodivala-Dilke, K. M., et al. (2007) Regulation of COX-2 mediated signaling by {alpha}3 type IV noncollagenous domain in tumor angiogenesis. Blood 110, 1168-1177. (Pubitemid 47281413)
27. Liang, X., Michael, B. D., Jessica, P., Hikaru, S., Margot, M., et al. (2011) Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc. Natl. Acad. Sci. USA 108, 9939-9944.
28. Floquet, N., Pasco, S., Ramont, L., Derreumaux, P., Laronze, J. Y., et al. (2004) The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent. J. Biol. Chem 279, 2091-2100. (Pubitemid 38084482)
29. Maeshima, Y., Colorado, P. C., Torre, A., Holthaus, K. A., Grunkemeyer, J. A., et al. (2000) Distinct anti-tumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem 275, 21340-21348. (Pubitemid 30481833)
30. Maeshima, Y., Yerramalla, U. L., Dhanabal, M., Holthaus, K. A., Barbashov, S., et al. (2001) Extracellular matrix derived peptide binds to alphavbeta3 integrin and inhibits angiogenesis. J. Biol. Chem. 276, 31959-31968.
31. Kawaguchi, T., Yamashita, Y., Kanamori, M., Endersby, R., Bankiewicz, K. S., et al. (2006) The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res. 66, 11331-11340. (Pubitemid 46009964)
32. Goto, T., Ishikawa, H., Matsumoto, K., Nishimura, D., Kusaba, M., et al. (2008) Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis. Int. J. Oncol. 33, 33-40.
33. Yao, B., He, Q. M., Tian, L., Xiao, F., Jiang, Y., et al. (2005) Enhanced antitumor effect of thecombination of tumstatin gene therapy and gemcitabine in murine models. Hum. Gene Ther. 16, 1075-1086. (Pubitemid 41324567)